Healthcare / Medical DevicesTaiwan
$370.00
-44.00 (-10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $144.0M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15.4B
P/E
97.4x
↑EV/EBITDA
54.3x
↑ROE
11.0%
↑Gross Margin
25.9%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
—
FCF margin
9.9%
FCF / Net income
1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.29B · net income $159.5M · FCF $227.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.29B | $2.29B | $1.99B | $1.84B | $1.89B |
| Net Income | $159.5M | $159.5M | $152.9M | $116.7M | $198.7M |
| EBITDA | $270.1M | $270.1M | $280.5M | $210.6M | $317.0M |
| EPS | — | — | 3.64 | 2.84 | 5.22 |
| Gross Margin | 25.9% | 25.9% | 27.8% | 27.4% | 30.9% |
| Operating Margin | 5.9% | 5.9% | 1.7% | 1.7% | 4.6% |
| Net Margin | 7.0% | 7.0% | 7.7% | 6.4% | 10.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.13 | 0.15 | 0.56 |
| Current Ratio | 2.14 | 2.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $227.8M | $227.8M | $144.0M | $47.4M | $-315.9M |
| Returns | |||||
| ROE | 11.0% | 11.0% | 11.1% | 9.1% | 24.3% |
| Valuation | |||||
| P/E | 97.37 | 97.37 | 16.59 | 29.40 | 16.00 |
| EV/EBITDA | 54.27 | 54.27 | 6.90 | 13.98 | 9.66 |
| P/B | 10.57 | 10.57 | 1.83 | 2.67 | 3.89 |
| Growth & Yield | |||||
| Revenue Growth | 15.3% | 15.3% | 8.3% | -2.6% | — |
| EPS Growth | — | — | 28.2% | -45.6% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+607.7%
Start / end P/E
n/dx → n/dx
EPS bridge
3.64 → n/d
Residual
+607.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.